

After having completed a doctorate degree in vascular physiopathology in France and a post-doctorate degree in vascular biology in Alberta, Dr. Bonnet settled in Québec city, as an associate professor at Université Laval and a researcher at the Research Centre of the IUCPQ where he continues his research in the cardiovascular field. Dr. Bonnet was named Fellow of American Heart Association and Director of the Canadian Research Chair in vascular pathology. This title, considered as one of the greatest honors in the scientific community, is allotted to researchers who showed leadership, creativity and exceptional competence in the advancement of fundamental and clinical research in the cardiovascular field. The accomplishments of Professor Bonnet led to the discovery of mechanisms causing pulmonary arterial hypertension, a fatal disease which strikes mainly young adults. His team also discovered two substances likely to treat this disease effectively. Drs Bonnet and Provencher are the founders and directors of the pulmonary hypertension research group. Since 2016, Drs Roxane Paulin and Olivier Boucherat, fundamental researchers, joined the group.

The group of Dr. Bonnet uses a multidisciplinary and translational approach (from genes to population) in order to study the molecular and cellular mechanisms involved in the development of the process of vascular and bronchial remodeling. This work allows the identification of new biomarkers, thus improving the identification and clinical management of individuals afflicted by PAH. His research also identified new therapeutic targets such as Pim-1, miR-204, PARP-1 and BRD4 in PAH.